Head and Neck cancer is the 6th most common form of cancer worldwide. For many patients, survival is measured in months, not years.MC-30 aims to give years of quality life back to many patients by correcting the underlying mutation that creates resistance to treatment


FSHD is one of the most common muscular dystrophies, with over 40,000 patients in the US. There are no FDA approved treatments for this disease. MC-DX4 aims to stop disease progression in patients by eliminating expression of the toxic DUX4 protein in muscle tissue.